EGFR and cancer: The number of target mapping pathways was higher than ErbB signaling pathways in cancer (hsa04012 number = 9), non-small cell lung cancer (hsa05223, number = 7), and EGR Tyrosine kinase inhibitors (hsa05219, number = 4).